Daewoong Pharmaceutical Receives Approval for Phase 3 Clinical Trial Plan of 'DWJ1248' for COVID-19 Prevention
[Asia Economy Reporter Minji Lee] Daewoong Pharmaceutical announced on the 25th that it has received approval from the Ministry of Food and Drug Safety of Korea for the Phase 3 clinical trial plan of ‘DWJ1248’ aimed at preventing COVID-19 in individuals exposed to the novel coronavirus.
Hot Picks Today
!["It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]](https://cwcontent.asiae.co.kr/asiaresize/93/2026052019230771274_1779272587.jpg)
"It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- Dramatic Agreement Reached on Eve of Samsung Electronics General Strike... Minister Kim Young-hoon: "Showcased Korea's Strength in Dialogue" (Update)
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company stated, “We will evaluate the positivity conversion rate within 14 days after exposure to the COVID-19 virus to assess the potential efficacy of DWJ1248,” adding, “We aim to confirm the infection prevention effect in high-risk groups such as close contacts and self-quarantined individuals exposed to the COVID-19 virus.”
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
